Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapacitabine in advanced CTCL
NCT00476554Phase 2Terminated
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Apr 2007
- Primary completion
- Mar 2012
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sapacitabine in cutaneous T-cell lymphoma (CTCL) (2 arms), sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoint: Response rate in overall skin disease. Started Apr 2007; status: terminated.
02
Drugs
sapacitabine
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00476554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00476554.